Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT01947790

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01947790
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01947790. Randomized; double masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2015-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease
Condition
LVM
Condition
Type 2 Diabetic Patients With IHD
Condition
Endothelial Function
Intervention (Drug)
pioglitazone group
Intervention (Drug)
Metformin group
Lead sponsor
Xiang Guang-da (class: other)

Record details

Record id
cardio:ct-nct01947790
Content hash
2dacf1a9cdda704d861ad7a7951276fd5263d62eab6ce671ac20c04442a16578